BCL2 and colorectal carcinoma: Further mechanism study found that HIF‐1α mediates the inhibition of miR‐338‐5p, interferes with the regulation of miR‐338‐5p on the downstream direct target IL‐6, mediates the activation of STAT3/BCL2 signalling pathway and enhances CRC resistance to oxaliplatin.36